Cancer Hijacks Bone Marrow to Create Immunosuppressive Macrophages
Researchers discover how tumors reprogram immune cell production in bone marrow, creating macrophages that help cancer evade treatment.
Summary
Scientists have uncovered how lung tumors manipulate bone marrow to produce immunosuppressive macrophages that help cancer evade the immune system. The study found that tumors activate the NRF2 pathway in bone marrow progenitor cells, creating a stress response that boosts production of monocytes while dampening their ability to fight cancer. These monocytes then travel to tumors and become macrophages that actively suppress immune responses. Importantly, blocking NRF2 restored natural killer cell and T cell function, improving checkpoint immunotherapy effectiveness in mouse models.
Detailed Summary
This groundbreaking research reveals a previously unknown mechanism by which cancers sabotage the immune system at its source - the bone marrow. Understanding this process could lead to more effective cancer treatments by preventing tumors from creating their own immunosuppressive environment.
Researchers analyzed the complete journey of immune cells from bone marrow progenitors to tumor-infiltrating macrophages in both mice and lung cancer patients. They used advanced techniques to map gene expression and chromatin accessibility across this cellular continuum.
The key discovery centers on the NRF2 pathway, typically involved in protecting cells from oxidative stress. Lung tumors remotely activate this pathway in bone marrow myeloid progenitors, creating a cascade effect. This activation enhances the production of monocytes while simultaneously reducing their interferon response - a critical anti-cancer mechanism. These compromised monocytes then migrate to tumors and differentiate into macrophages that actively suppress immune responses.
When researchers deleted the NRF2 gene or used drugs to block its activity, the immunosuppressive macrophages could no longer survive effectively in the tumor environment. This restoration allowed natural killer cells and T cells to resume their cancer-fighting functions and significantly improved the effectiveness of checkpoint blockade immunotherapy.
The findings suggest that targeting this bone marrow reprogramming early in cancer development could prevent the establishment of immunosuppressive tumor environments, potentially making existing immunotherapies more effective across a broader range of patients.
Key Findings
- Lung tumors remotely activate NRF2 pathway in bone marrow to create immunosuppressive monocytes
- NRF2 activation enhances myelopoiesis while dampening interferon responses in progenitor cells
- Blocking NRF2 restored natural killer and T cell anti-tumor immunity in mouse models
- NRF2 inhibition significantly enhanced checkpoint blockade immunotherapy effectiveness
- This mechanism represents a targetable early intervention point for cancer treatment
Methodology
Researchers performed paired transcriptome and chromatin accessibility analysis across the continuum from bone marrow myeloid progenitors to circulating monocytes to tumor-infiltrating macrophages. Studies included both mouse models and human lung cancer patients, with genetic deletion and pharmacological inhibition experiments to validate NRF2's role.
Study Limitations
The study was limited to lung cancer models and patients, so generalizability to other cancer types remains unclear. Additionally, since only the abstract was available, details about sample sizes, specific drug interventions, and long-term safety profiles of NRF2 inhibition are not provided.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.